2002
Endothelin-1 gene polymorphism in the identification of patients at risk for malignant ventricular arrhythmia
KOZÁK, Milan, Lydie IZAKOVIČOVÁ HOLLÁ, Lubomír KŘIVAN, Anna VAŠKŮ, Milan SEPŠI et. al.Základní údaje
Originální název
Endothelin-1 gene polymorphism in the identification of patients at risk for malignant ventricular arrhythmia
Autoři
KOZÁK, Milan (203 Česká republika, garant), Lydie IZAKOVIČOVÁ HOLLÁ (203 Česká republika), Lubomír KŘIVAN (203 Česká republika), Anna VAŠKŮ (203 Česká republika), Milan SEPŠI (203 Česká republika), Bořivoj SEMRÁD (203 Česká republika) a Jiří VÁCHA (203 Česká republika)
Vydání
Medical Science Monitor (International Medical Journal of Experimental and Clinical Research), USA, International Scientific Literature, Inc, 2002, 1234-1010
Další údaje
Jazyk
angličtina
Typ výsledku
Článek v odborném periodiku
Obor
30201 Cardiac and Cardiovascular systems
Stát vydavatele
Spojené státy
Utajení
není předmětem státního či obchodního tajemství
Kód RIV
RIV/00216224:14110/02:00007238
Organizační jednotka
Lékařská fakulta
Klíčová slova anglicky
gene; endothelin; polymorphism; ET-1; arrhythmia; defibrillator
Štítky
Změněno: 13. 5. 2003 15:03, prof. MUDr. Lydie Izakovičová Hollá, Ph.D.
Anotace
V originále
The endothelins are peptides with vasoconstriction and growth-promoting properties. Endothelin-1 (ET-1) is known for its direct positive inotropic and chronotropic effects on isolated heart, and for growth effects. The aim of this pilot study was to investigate the frequency distribution of a common polymorphism of the endothelin gene and its possible relation to the hemodynamic consequences of malignant ventricular arrhythmia in patients with structural heart disease. We studied 26 consecutive patients with malignant ventricular arrhythmia and implantable cardioverter defibrillators (ICD), mean age 62.7 years, mean LVEF 0.37. The Taq polymorphism of ET-1 was detected using our original PCR method. Out of the 26 patients, 9 (34%) had reccurent palpitations and 8 (30.8%) had syncopes during their malignant arrhythmic episodes. 19 of the patients were receiving amiodarone after ICD implantation, 7 were not. 15 patients had the (++) and 11 had (+-) ET-1 genotype, none had the (--) genotype. The risk of syncopes was associated with the (++) genotype (p=0.01). Patients with amiodarone had a significantly higher frequency of the (++) genotype (p=0.011). All our results suggested that the presence of the (++) ET-1 genotype in patients with structural heart disease, severe left ventricular dysfunction, and malignant ventricular arrhythmia put these patients at a higher risk of hemodynamic collapse during arrhythmic episodes.
Návaznosti
MSM 141100002, záměr |
|